

International Pancreatic Cancer Forum – *Global Trends in FOLFIRINOX treatment for Pancreatic Cancer*

國際胰臟癌論壇

Date: 27th July, 2019 13:00-17:20

Venue: Conference Rm 401, 4F, Hall 1, Taipei Nangang Exhibition Hall

日期：7/27(六)下午13:30~17:20

地點：南港展覽館4樓401會議室(地址：台北市南港區經貿二路1號4樓)

Organizer: Taiwan Pancreas Society, Taiwan Oncology Society, SynCore Biotechnology, Taiwan Bio Industry Organization

主辦單位:台灣胰臟醫學會, 中華民國癌症醫學會, 杏國新藥股份有限公司

Time	Topic	Speaker
13:00-13:30	Registration	
13:30-13:50	Opening Remarks	Dr. Shou-Mei Wu , Director General of Taiwan Food and Drug Administration Dr. Li-Tzong Chen , President of Taiwan Oncology Society Dr. Ta-Sen Yeh , President of Taiwan Pancreas Society Dr. Muh-Hwan Su , General manager of SynCore Biotechnology
Session Moderator: Dr. Ta-Sen Yeh, President of Taiwan Pancreas Society		
13:50-14:20	The experience of mFOLFIRINOX for patients with pancreatic cancer	Dr. Li Yuan Bai Director, Division of Hematology and Oncology, China Medical University Hospital, Taiwan
14:20-14:50	The Korea experience of FOLFIRINOX in pancreatic cancer	Dr. Hong Jae Chon Associate Professor, Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Gyeonggi-Do, South Korea
14:50-15:10	Coffee Break	
Session Moderator: Dr. Li-Tzong Chen, President of Taiwan Oncology Society		
15:10-15:40	The U.S. experience of FOLFIRINOX in pancreatic cancer	Dr. Philip Agop Philip Karmanos Cancer Institute, Wayne State University, Leader, GI and Neuroendocrine Oncology, Vice President of Medical Affairs USA
15:40-16:10	The Hungary experience of FOLFIRINOX in pancreatic cancer	Dr. Zsuzsanna Pápai Professor, Department of Oncology, Magyar Honvédség Egészségügyi Központ, Budapest, Hungary

16:10-16:40	The France experience of FOLFIRINOX in pancreatic cancer	Dr. Jean-Philippe Metges Professor, CHRU Brest-Hôpital Morvan Brest, France
-------------	--	---

16:40-17:10	Panel Discussion	Dr. Li Yuan Bai , Director, China Medical University Hospital, Taiwan Dr. Hong Jae Chon , Associate Professor, CHA Bundang Medical Center, South Korea Dr. Jean-Philippe Metges , Professor, CHRU Brest-Hôpital Morvan Dr. Philip Agop Philip , Vice President of Medical Affairs USA Dr. Zsuzsanna Pápai , Professor, Magyar Honvédség Egészségügyi Központ, Budapest, Hungary. Dr. Li-Tzong Chen , President of Taiwan Oncology Society Dr. Ta-Sen Yeh , President of Taiwan Pancreas Society Dr. Muh-Hwan Su , General Manager, SynCore Biotechnology
17:10-17:20	Closing Remarks	Dr. Muh-Hwan Su , General manager of SynCore Biotechnology

學會教育積分：(申請中)

台灣外科醫學會
台灣消化系內視鏡醫學會
台灣消化系醫學會
台灣內視鏡外科醫學會
中華民國癌症醫學會

不收費需事先線上報名

報名連結如下

Chinese: <https://bit.ly/2KwOUSR>

English: <https://bit.ly/2N7QnBg>

報名電話：02-2760-3688*2854蕭小姐

報名傳真：02-2763-9287

Email Add : YHHsiao2@syncorebio.com

Curriculum vitae

Name: Li-Yuan Bai, M.D., M.M.S., Ph.D.
E-mail: lybai6@gmail.com
Current Position: Feb. 2017: Professor, China Medical University
Jan. 2018: Director, Division of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan
Jul. 2018: Deputy Director, Clinical Trial Center, China Medical University Hospital
Education and Board: Sep. 1987 – Jun. 1994: School of Medicine, National Yang-Ming University, Taipei, Taiwan
Mar. 1997: Certification of Educational Commission for Foreign Medical Graduates, USA
Oct. 2001: Certified Doctor of Internal Medicine
Nov. 2003: Certified Doctor of Medical Oncology
Feb. 2004: Member of Taiwan Academy of Hospice Palliative Medicine
Nov. 2004: Certified Doctor of Hematology
Jul. 2007: Master of Medical Science, Graduate Institute of Medical Science, China Medical University, Taichung, Taiwan
Jun. 2011: Ph.D., Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan
Previous Employments: Jun. 1998 - Dec. 2004: Resident doctor, Department of Medicine, Taipei Veterans General Hospital (VGH), Taipei, Taiwan
Dec. 2004 – Jul. 2005: Visiting staff, Department of Medicine, Yilan Hospital
Mar. 2008 – May. 2009: Visiting scholar at College of Pharmacy, The Ohio State University, Columbus, OH, USA
Aug. 2005 – present : Attending Physician, Division of Hematology and Oncology, China

Publications (after 2016)

1. Satoh T, Kang YK, Chao Y, Ryu MH, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Tanimoto M, Chen LT, Boku N. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. *Gastric Cancer* 2019 (accepted)
2. Cheng-Wen Lin, Hsien-Kuo Chin, Shou-Lun Li, Chang-Fang Chiu, Jing-Gung Chung, Zi-Yin Lin, Chia-Yung-Wu, Ying-Chen Liu, Yung-Ting Hsiao, Chia-Hsien Feng, Li-Yuan Bai*, and Jing-Ru Weng*. Ursolic acid induces apoptosis and autophagy in oral cancer cells. *Environ Toxicol* 2019 (accepted)
3. Chia-Yu Chen, Chang-Fang Chiu, Li-Yuan Bai*. Treatment of pembrolizumab-induced cutaneous lesions with ruxolitinib. *Eur J Cancer* 2019 Apr 12;113:69-71.
4. Weng JR, Bai LY, Chiu SJ, Chiu CF, Lin WY, Hu JL, Shieh TM. Divaricoside Exerts Antitumor Effects, in Part, by Modulating Mcl-1 in Human Oral Squamous Cell Carcinoma Cells. *Comput Struct Biotechnol J* 2019 Jan 26;17:151-159.
5. Jing-Ru Weng, Ching-Shih Chen, Chang-Fang Chiu Chiu, Jing-Lan Hu, Chia-Hsien Feng, Chiung-Yao Huang, Li-Yuan Bai*, Jyh-Horng Sheu*. A 9,11-secoesterol from soft coral induces apoptosis and autophagy in MCF-7 breast cancer cells. *Mar Drugs* 2018 Jul 17;16(7).pii:E238.
6. Lien MY, Chou CH, Lin CC, Bai LY, Chiu CF, Yeh SP, Ho MW. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study. *PLoS One* 2018 Jun 8;13(6):e0197851.
7. Kuo CY, Wang PN, Hwang WL, Tzeng CH, Bai LY, Tang JL, Chang MC, Lin SF, Chen TY, Chen YC, Tan TD, Hsieh CY, Lin C, Lai C, Miljkovic D, Chang CS*. Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study. *Ther Adv Hematol* 2018 Mar;9(3):65-78.
8. Weng JR*, Bai LY, Ko HH, Tsai YT. Cyclocommunol induces apoptosis in human oral squamous cell carcinoma partially through a Mcl-1-dependent mechanism. *Phytomedicine* 2018 Jan 15;39:25-32.
9. Yoon-Koo Kang, Narikazu Boku, Taroh Satoh, Min-Hee Ryu, Yee Chao, Ken Kato, Hyun Cheol Chung, Jen-Shi Chen, Kei Muro, Won Ki Kang, Kun-Huei Yeh, Takaki Yoshikawa, Sang Cheul Oh, Li-Yuan Bai, Takao Tamura, Keun-Wook Lee, Yasuo Hamamoto, Jong Gwang Kim, Keisho Chin, Do-Youn Oh, Keiko Minashi, Jae Yong Cho, Masahiro Tsuda, Li-Tzong Chen. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5.
10. Weng JR*, Bai LY, Lin WY. Identification of a Triterpenoid as a Novel PPAR γ Activator Derived from Formosan Plants. *Phytother Res*. 2017 Nov;31(11):1722-1730. doi: 10.1002/ptr.5900.
11. Bai LY, Chiu CF, Chiu SJ, Chu PC, Weng JR. FTY720 induces autophagy-associated apoptosis in human oral squamous carcinoma cells, in part, through a reactive oxygen species/Mcl-1-dependent mechanism. *Sci Rep* 2017 Jul 17;7(1):5600. doi: 10.1038/s41598-017-06047-9.
12. Tsai WC, Bai LY, Chen YJ, Chu PC, Hsu YW, Sargeant AM, Weng JR*. OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling. *Oncotarget* 2017 Apr 25;8(17):29233-29246. doi: 10.18632/oncotarget.16450

13. Weng JR*, Bai LY, Lin WY, Chiu CF, Chen YC, Chao SW, Feng CH. A Flavone Constituent from *Myoporum bontioides* Induces M-Phase Cell Cycle Arrest of MCF-7 Breast Cancer Cells. *Molecules* 2017 Mar 15;22(3). pii: E472.
14. Chang-Fang Chiu, Horng-Ren Yang, Mei-Due Yang, Long-Bin Jeng, Tse-Yen Yang, Aaron M. Sargeant, Li-Yuan Bai*. Palliative gastrectomy prolongs survival of metastatic gastric cancer patients with normal preoperative CEA or CA19-9 values: a retrospective cohort study. *Gastroenterol Res Pract* 2016;2016:6846027.
15. Chiu CF, Weng JR, Jadhav A, Wu CY, Sargeant AM, Bai LY*. T315 decreases acute myeloid leukemia cell viability through a combination of apoptosis induction and autophagic cell death. *Int J Mol Sci* 2016 Aug 15;17(8). pii: E1337.
16. Chang-Fang Chiu, Horng-Ren Yang, Mei-Due Yang, Long-Bin Jeng, Aaron M. Sargeant, Su-Peng Yeh, Li-Yuan Bai*. The role of adjuvant chemotherapy for patients with stage II and stage III gastric adenocarcinoma after surgery plus D2 lymph node dissection: a real-world observation. *Springerplus* 2016 Jun 16;5(1):728.
17. Wu CH, Bai LY, Tsai MH, Chu PC, Chiu CF, Chen MY, Chiu SJ, Chiang JH, Weng JR*. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents-A drug repurposing strategy. *Sci Rep.* 2016 Jun 9;6:27540. doi: 10.1038/srep27540.
18. Bai LY, Chiu CF, Chu PC, Lin WY, Chiu SJ, Weng JR*. A triterpenoid from wild bitter gourd inhibits breast cancer cells. *Sci Rep.* 2016 Mar 1;6:22419. doi: 10.1038/srep22419.

Curriculum Vitae

- **Name** **Hong Jae Chon, MD, PhD**
- **Address** Associate Professor,
Medical Oncology, Department of Internal Medicine,
CHA Bundang Medical Center, CHA University,
59 Yatap-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13496, Korea
- **Contact** Phone: 82-31-780-3737 E-mail: minidoctor@cha.ac.kr or hongjaechon@gmail.com

▪ Education

1998.3.-2005.2. **MD, Yonsei University College of Medicine, Seoul, Korea.**

2008.3.-2018.8. **PhD, Yonsei Graduate School, Seoul, College of Medicine, Korea,**

Supervised by Professor [Joong Bae Ahn](#)

Doctoral thesis: "Combination immunotherapy of oncolytic virus and immune checkpoint inhibitor in renal cell carcinoma"

▪ Professional Experiences

2005.3.-2006.2. **Rotating internship, Severance Hospital,**

Yonsei University College of Medicine, Seoul, Korea

2006.3.-2010.2. **Residency in Internal Medicine, Severance Hospital,**

Yonsei University College of Medicine, Seoul, Korea

2013.5.-2014.2 **Clinical Fellow, Division of Medical Oncology, Severance Hospital,**

Yonsei University College of Medicine, Seoul, Korea

2014.3.-2015.8 **Clinical Research Professor, Division of Medical Oncology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea**

2015.9.- **Assistant Professor, Medical Oncology,**

CHA Bundang Medical Center, CHA University, Seongnam, Korea

2016.1- Co-Director, Laboratory of Tumor Vasculature and Microenvironment, CHA University,

Pangyo, Seongnam, Korea (<https://sites.google.com/view/ltio>)

2019.3.- Associate Professor, Medical Oncology,

CHA Bundang Medical Center, CHA University, Seongnam, Korea

▪ Full list of Publications

1. Kim C*, [Chon HJ](#)*, Kim JH, Jung M, Nam JM, Kim HS, Kang B, Chung HC, Rha SY. Randomized phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. *European Journal of Cancer* 2018 (IF 7.191) **(*Co-first author)**
2. [Chon HJ](#)*, Lee WS*, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Kim JH, Ahn JB, Kim JH, Kim C. Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade. *Clinical Cancer Research* 2019 (IF 10.199)
3. [Chon HJ](#)*, Kim C*, Cho A, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M, Rha SY. The Clinical Implications of FDG-PET/CT Differ According to Histology in Advanced Gastric Cancer. *Gastric Cancer* 2018 (IF 5.454) **(E-pub)**
4. Kim C, Kim WR, Kim KY, [Chon H](#), Beom SH, Kim H, Jung M, Shin SJ, Kim N, Ahn JB. Predictive Nomogram for Recurrence of Stage I Colorectal Cancer Following Curative Resection. *Clinical Colorectal Cancer* 2018 (IF 4.507);17(3):e513-e518.
5. Kim HS, [Chon HJ](#), Kim HK, Shin SJ, Wacheck Volker, Gruver AM, Kim JS, Rha SY, Chung HC. MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis. *Journal of SUGGICAL ONCOLOGY* 2018 (IF 2.886)
6. Kim C*, Lee C*, [Chon HJ](#)*, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, Rha SY. PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. *Oncotarget* 2017 (IF 5.168), 8(69):113494-501 **(*Co-first author)**
7. Park HS, Park JS, Chun YJ, Roh YH, Moon J, [Chon HJ](#), Choi HJ, Park JS, Lee DK, Lee SJ, Yoon, DS, Jeung HC. Prognostic factors and scoring model for survival in metastatic biliary tract cancer. *Cancer Res Treat* 2017 (IF 3.230)

8. **Chon HJ***, Hyung WJ*, Kim, C, Park SH, Kim JH, Park CH, Ahn JB, Kim HK, Chung HC, Rha SY, Noh SH, Jeung HC. Different implication of gastric signet ring cell carcinoma. *Annals of Surgery* 2017 (IF 9.203)
9. Kim C, Yoo KH, Kim MH, **Chon HJ**, Lee SI, Koh S, Lee HY, Lee HR, Kim KS, Choi YD, Rha SY, Lee SJ, Kim HS. Different Subtypes of Epithelioid Sarcoma and Their Clinical Implication: Long-term Multi-Institutional Experience with a Rare Sarcoma. *APMIS* 2017 (IF 1.933), 125:223-229
10. Kim C, Kim EK, Jung H, **Chon HJ**, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Kim SH, Kim HS. Prognostic Implications of PD-L1 Expression in Patients with Soft Tissue Sarcoma. *BMC Cancer* 2016 (IF 3.265), 16:434
11. Lim SM, Kim YN, Park KH, Kang BD, **Chon HJ**, Kim C, Kim JH, Rha SY. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. *BMC Cancer* 2016 (IF 3.265), 16:385
12. Kim C, Yang H, Park I, **Chon HJ**, Kim JH, Kwon WS, Lee WS, Kim TS, Rha SY. Rho GTPase RhoJ is associated with gastric cancer progression and metastasis. *Journal of Cancer* 2016 (IF 3.609), 7(11):1550-1556
13. **Chon HJ***, Kim HR*, Shin E, **Kim C**, Heo SJ, Lee C, Park JK, Noh SH, Chung HC, Rha SY. The Clinicopathological Features and Prognostic Impact of ALK-positivity in Resected Gastric Cancer Patients. *Annals of Surgical Oncology* 2015 (IF 3.943), 22(12):3938-45
14. Park JS, Jeung HC, Rha SY, Ahn JB, Kang BD, **Chon HJ**, Hong MH, Lim ST, Yang WI, Nam CM, Chung HC. M. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane. *Cancer Chemother Pharmacol* 2014 (IF 2.808)
15. Kim C, **Chon HJ**, Kang B, Kim K, Jeung HC, Chung HC, Noh SH, Rha SY. Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. *BMC Cancer* 2013 (IF 3.319), 13(1):394.
16. **Chon HJ**, SY Rha, Park HS, Shin SJ, Kim HS, Roh JK, Noh SH, Chung HC, Jeung HCl. Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. *Cancer Chemotherapy and Pharmacology* (IF 2.769) October 2011, Volume 68, Issue 4, pp 991-999,
17. Hong MH, Koo HM, Choi J, Ahn JR, **Chon HJ**, Kim C, Lee ST. A case of nephrogenic systemic fibrosis after gadolinium-based contrast agent injection. *Korean Journal of Medicine* 2010, 78(1):127-131.
18. **Chon HJ**, Rha SY, Im CK, Kim C, Hong MH, Kim HR, Ahn JR, Noh SH, Chung HC, Jeung HC. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. *Cancer Research and Treatment* 2009 (IF 2.975), 41(4):196-204.
19. Kim C, Shin E, Hong S, **Chon HJ**, Kim HR, Ahn JR, Hong MH, Yang WI, Roh JK, Rha SY. Clinical value of ezrin expression in primary osteosarcoma. *Cancer Research and Treatment* 2009 (IF 2.975), 41(3):138-144.
20. Ahn JR, Hong M, Kim C, Hong MH, **Chon HJ**, Kim HR, Jeung HC, Hyung WJ, Lee SS, Chung HC, Noh SH, Rha SY. Prognosis of pN3 stage gastric cancer. *Cancer Research and Treatment* 2009 (IF 2.975), 41(2):73-79.
21. Hong MH, Kim HS, Kim C, Ahn JR, **Chon HJ**, Shin SJ, Ahn JB, Chung HC, Rha SY. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. *Cancer Research and Treatment* 2009 (IF 2.975), 41(2):67-72.

▪ Presentations

1. Oral presentation on “Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer” (Korean Association for Clinical Oncology Meeting, 2010)
2. Oral presentation on “BIM deletion polymorphism as a biomarker in advanced gastric cancer” (Japanese Gastric Cancer Association for Clinical Oncology Meeting, Osaka, Japan, 2013)
3. Oral presentation on “A phase IB/II Trial of FGF trap and paclitaxel combination treatment in patient with advanced gastric cancer” (KCSG Methodology Workshop, Seoul, Korea, 2014) Award for outstanding presentation
4. Oral presentation on “The Clinicopathological Features and Prognostic Impact of ALK-positivity in Resected Gastric Cancer Patients” (Global Academic Program 2014 Conference)
6. Prognostic impact of different FDG-PET uptake according to histology in advanced gastric cancer (ASCO Annual Meeting, Chicago, United States, 2015)

7. Randomized phase II trial comparing 4 doublets as a front-line treatment in Asian patients with recurrent/metastatic gastric cancer (ASCO Annual Meeting, Chicago, United States, 2016)
8. Adjuvant chemotherapy in gastric cancer (The 17th Clinical Trial Education Workshop, Seoul, Korea, 2017)
9. Adjuvant Treatment of pancreatic cancer (KCSG, Hepatobiliary & pancreatic cancer symposium, Seoul, Korea, 2017)
10. STING agonist modulates tumor immune microenvironment of NSCLC to potentiate the efficacy of PD-1 immune checkpoint blockade (CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, Mainz/Frankfurt, Germany, 2017)
11. Oncolytic virotherapy with JX-594 (Pexa-Vec) modulates tumor immune microenvironment to potentiate the efficacy of immune checkpoint blockade (Keystone symposia, Montreal, Canada, 2018)
12. Combination of oncolytic vaccinia virus and immune checkpoint blockade overcomes resistance to immunotherapy in renal cell carcinoma (AACR Annual Meeting, Chicago, United States, 2018)
13. STING signaling has a favorable clinical implication in colorectal cancer (CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference, New York, United States, 2018)
14. Management of biliary cancer: metastatic disease (The 27th Clinical Trial Education Workshop, Seoul, Korea, 2018)
15. An oral dual inhibitor of IDO and TDO enhances anti-cancer immunity and synergizes with immune checkpoint blockade (ESMO 2018, Munich, Germany)
16. STING, an immune biomarker for colorectal cancer (ESMO Asia 2018, Singapore)
17. Current evidence and future perspective of immunotherapy in HCC (HCC Symposium, KSMO, Seoul, Korea, 2018)

▪ **Patents**

1. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy (PCT/US2018/028952, 2018)
2. Novel IDO/TDO inhibitors (62647483, 2018)

PHILIP AGOP PHILIP, M.D., Ph.D., F.R.C.P., F.A.B.C.

CURRENT POSITION

Professor of Oncology, Pharmacology and Medicine
Kathryn Cramer Endowed Chair in Cancer Research
Vice President of Medical Affairs
Department of Oncology
Karmanos Cancer Institute
Wayne State University School of Medicine

Office Address #1

Karmanos Cancer Institute
4100 John R Street
Mail Code: HW04HO
Detroit, MI 48201 USA
Phone: 1-313-576-8728
Fax: 1-313-576-8767
E-mail: philip.karmanos@hotmail.com

Office Address #2

Karmanos Cancer Center at
Farmington Hills (Weisberg)
31995 Northwestern Hwy.
Farmington Hills, MI 48334
Phone: 1-248-538-4701

Education

Ph.D. in <i>Clinical Pharmacology and Pharmacogenetics</i> , University of London, Guy's Hospital Medical School, London, UK	1982 - 1986
M.D. , University of Baghdad, College of Medicine, Baghdad, Iraq	1971 - 1977
Baccalaureate , Baghdad College, American Jesuit Fathers, Baghdad, Iraq	1965 - 1971

Post-Graduate Training

Fellowship Course in Leadership, Advisory Board Company, D.C.	2014 - 2015
Fellow in Medical Oncology, MD Anderson Cancer Center, Houston, Texas	1993 - 1995
Senior Registrar in Medical Oncology, University of Oxford and Imperial Cancer Research Fund, Clinical Oncology Unit, Churchill Hospital, Oxford, United Kingdom	1988 - 1993
Registrar in Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester, University of Manchester, United Kingdom	1988 - 1988
Registrar in Medical Oncology, Charing Cross Hospital, University of London, London, United Kingdom	1986 - 1988
Clinical Research Fellow and Honorary Registrar, Department of Clinical Pharmacology and Lymphoma Unit, Guy's Hospital Medical School, University of London, London, United Kingdom	1982 - 1986
Resident Medical Officer, St. Raphael Hospital, Baghdad, Iraq	1981 - 1982
Lecturer in Clinical Pharmacology, Baghdad University Medical College, Baghdad, Iraq	1981 - 1982

Senior Resident in Internal Medicine, Medical City Teaching Hospital, University of Baghdad, Iraq 1980 - 1981

Resident in Internal Medicine, Al-Taji Hospital, Baghdad, Iraq 1978-80

Intern in Internal Medicine and General Surgery, Medical City Teaching Hospital, University of Baghdad, Baghdad, Iraq 1977 - 1978

Faculty Appointments

Professor in Pharmacology (secondary appointment) 2016 - present

Endowed Dr. Kathryn Cramer Professor of Cancer Research 2015 - present

Professor with Tenure, Department of Oncology with secondary appointment at Dept of Internal Medicine, School of Medicine, Wayne State University, Detroit, MI, USA 2010 - present

Professor with Tenure, Department of Internal Medicine, Wayne State University, Detroit, MI 2006 - present

Clinical Professor in Oncology, Karmanos Cancer Institute, NCI-designated Comprehensive Cancer Center, Detroit, MI 2003 - 2006

Professor (Clinician-Educator Track) in Internal Medicine, Wayne State University, School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI 2003 - 2006

Associate Professor in Oncology, Karmanos Cancer Institute, NCI-designated Comprehensive Cancer Center Detroit, MI 1998 - 2003

Associate Professor (Clinician-Educator Track) in Medicine, Wayne State University, School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI 1998 - 2003

Assistant Professor (Clinician-Educator Track), Karmanos Cancer Institute, NCI-designated Comprehensive Cancer Center, Wayne State University, School of Medicine, Department of Internal Medicine, Division of Hematology/Oncology, Detroit, MI 1995 - 1998

Hospital or Other Professional Appointments

Chair, GI Committee, SWOG 2019 -

Vice President for Medical Affairs, Karmanos Cancer Hospital, Detroit 2012 - present

President of Medical Staff, Karmanos Cancer Hospital, Detroit 2010 - 2012

Leader of Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team 2006 - present

Attending Physician at Karmanos Cancer Hospital 2005 - present

Attending Physician in Hematology/Oncology at the Detroit Medical Center (DMC), Detroit, MI. Privileges at Harper University Hospital, Detroit Receiving Hospital and Hutzel Hospital 1995 - present

COMMITTEES

Member, Scientific Committee: ESMO 21st Annual World Congress on Gastrointestinal Cancer 2018 - present

Member, Department of Oncology Review Committee, School of Medicine 2018

Member, P&T/Selective Salary Committee, Dept of Oncology 2016 - present

Member, Metastatic Pancreatic Cancer Guideline Panel, ASCO 2018

Member, ACCC HCC Advisory Committee,	2018- present
Member, Working Group, North America Neuroendocrine Tumors Society (NANETS),	2018 - present
Chair, Budget Advisory Committee, School of Medicine, WSU	2017 - present
Leader of hepatopancreaticobiliary track and member of planning committee of ASCO GI	2017 - present
Member, Recruitment and retention subcommittee, KCI	2017
Poster Judging Panel for the Medical Student Research Symposium	2017, 2018
Abstract selection Committee, Annual NANET meeting	2011, 2015-2017
Member, Promotion & Tenure Committee, WSU	2016
Ad hoc external member, Promotions Committee, Harvard Medical School	2016 -
Member, Caris, Center of Excellence GI Tumor Group,	2016 -
Member, Policy Committee, KCC	2015 - present
Member, Advisory Board, The Skyfoundation, Inc	2015, 2017
Member of Planning Committee, led the Medical Oncology Working Group, Annual Karmanos Meeting	2017 -
Chair, Data Safety Monitoring Committee, Aslan Pharma	2017 -
Member, KCC Quality and Compliance Subcommittee,	2017 -
Member, Weisberg Expansion Committee,	2015 -
Member, Steering Committee, Phase III APACT Trial,	2015
Member, Physician Lab Advisory Council	2016 -
Member, Data Safety Monitoring Committee, Lexicon #1606.301-303	2015 and 2016
Member, ad hoc, Dr Rosner PT Committee, Department of Dermatology and CMMG	2014 - present
Member, Organizing Committee, International GI Symposium, Turkey	2014 - 2020
Member, Hearing Panel, WSU	2014 - 2020
Member, Professionalism Committee, WSU	2014 -present
Member, KCI/McLaren Integration Steering Committee	2014, 2018
Member, ASCO Metastatic Pancreas Cancer Guideline Committee	2014 - present
Member, Editorial Board for "Together we're better", KCI/McLaren	2014 - present
Grant reviewer, Molecular Therapeutics Program	2014 - present
Member of GI/NET track, McLaren Medical Oncology Care Plans	2014 - present
Member, Hospitalist Liaison Committee	5/5/2014
Member, Scientific Strategy Planning Retreat	2014 - present
Member, International Pancreatic Cancer Forum	2012 - present
Member, Medical Advisory Board, Pancreatic Action Network (PanCan)	2012 - present
Chair, Clinic Improvement Initiative Working Group	2012 - present
Chair, Utilization Review Committee, KCC	2012 - present
Chair, HPIC, KCC	2012 - present
Member, Steering Committee, Molecular Therapeutics Program, KCI	2011 - 2014
Member, Executive Committee of the School of Medicine, Wayne State University	2011 - present
Department of Oncology P&T and Salary and Appointment Committee, Karmanos Cancer Institute	2011 - 2014
Co-Leader of the GI Subcommittee of the California NO1 Consortium	2011 - 2012
President, KCI Medical Executive Committee	2010 - present
Member, KCC Board of Directors	2008 - 2010
President Elect, Medical Staff Leadership Council, Karmanos Cancer Center	2003 - 2011
Chair, Protocol Review and Monitoring Committee	2009 - 2014
Member, IDEA (International Development and Education Award) through ASCO	2007 - 2010
Member, Executive Committee of the Faculty Senate, Wayne State University	2007 - 2008
Member, Chair of Pathology Search Committee, Dean's Office, School of Medicine, Wayne State University	2006 - present
Member, Clinical Leadership Council, Karmanos Cancer Institute	2006 - 2010
Member, Financial Conflict of Interest Committee, Wayne State University	2006 - 2007
Leader, Organizing Committee, State of Science Meeting on Pancreas Cancer Sponsored by NCI (November 30 th & December 1 st , 2007)	

Member, ASCO Educational Committee, Non-Colorectal GI	2005 - 2008
School of Medicine Committee to review the Department of Surgery	2005
Member, MD/PhD admission committee, School of Medicine, Wayne State University	2005
Member, CTEP site visit to New York University, Cancer Center	2004
Member of the Scientific Leadership Council, Karmanos Cancer Institute	2003 - 2011
Leader of Pancreas Cancer Subcommittee and member of the Steering Committee for GI Cancer, Southwest Oncology Group (SWOG)	2000 - present
Member of the Intergroup Task Force on Pancreatic Cancer	2000 - present
Member, DMC Hematology/Oncology Pharmacy Therapeutics Subcommittee	1999 - 2002
Member, Fellows Education Committee, Oncology Fellowship Oncology Program, WSU	1999
Wertz Clinical Care Center Operational Focus Group, Karmanos Cancer Institute	1998
Member, Drug Development Program, Karmanos Cancer Institute	1997 - 2005
Member, Wertz Business/Clinical Audit Committee, Karmanos Cancer Institute	1997 - 2000
Member in the Protocol Review Committee, Karmanos Cancer Institute	1996 - 2003
Member, Primary Cancer Prevention Task Force, Karmanos Cancer Institute	1995 - 2000
Human Applications Group, Institute of Chemical Toxicology, Wayne State University	1995 - 2000

SERVICE

Patient Care

Medical Oncology – Karmanos Cancer Hospital, Harper University Hospital, Detroit Receiving Hospital, and Hutzel Hospital, Detroit, MI	In-Patients
Medical Oncology - Karmanos Cancer Hospital, Harper University Hospital, Detroit Receiving Hospital, and Hutzel Hospital, Detroit, MI	Consults
GI Multidisciplinary Program – One clinic/week (Monday)	Outpatients
Farmington Karmanos Center Clinic - Two clinics/week (Tuesday/Wednesday)	

Major Professional Societies

• European Society of Medical Oncology (ESMO)	2017 -
• International Liver Cancer Association (ILCA)	2010 - present
• North America Neuroendocrine Tumor Society (NANET)	2015 -
• American Pancreatic Association (APA)	2000 - present
• American Society of Clinical Pharmacology and Therapeutics (ASCPT)	1998 - 2004
• American College of Physicians (ACP)	1998 - 2000
• NSABP	1998 - 2000
• Society of Toxicology, Michigan Regional Chapter	1996 - 2004
• Southwest Oncology Group (SWOG)	1995 - present
• American Society of Clinical Oncology (ASCO)	1995 - present
• American Association for Cancer Research (AACR)	1995 - present
• Pharmacology and Molecular Mechanisms Group (PAMM) of the European Organization for Research and Treatment of Cancer (EORTC)	1990 - present

Board Certifications

• ABIM re-certification in Medical Oncology	2015 - 2025
• ABIM certification in Medical Oncology	2005 – 2015
• ABIM certification in Internal Medicine	2004 - 2014
• Accreditation in the Subspecialty of Medical Oncology by the Joint Committee for Higher Medical Training of the United Kingdom and the Royal College of Physicians of the UK	1991
• M.R.C.P. (Internal Medicine Diploma), Royal College of Physicians of the United Kingdom	1985
• Fellowship of the Royal College of Physicians (FRCP) of the UK	